Exhibit 10.6
AMENDMENT TO
KEY EMPLOYEE AGREEMENT
          This Amendment, effective as of December 31, 2008 (“Effective Date”),
is entered into by and between Watson Pharmaceuticals, Inc., a corporation
organized under the laws of the State of Nevada (the “Company”), and Thomas R.
Russillo (the “Executive”). This Amendment amends that certain Key Employee
Agreement entered into by and between the Company and Executive dated effective
as of September 5, 2006 (the “Agreement”). This Amendment to the Agreement,
together with the Agreement, constitutes the entire Agreement as amended through
the Effective Date.
          1. Definition of Good Reason. Effective as of the Effective Date,
Section 6.5(a) of the Agreement is hereby amended in its entirety to read as
follows:
          (a) Definition of “Good Reason.” For purposes of this Agreement, “Good
Reason” shall mean any one of the following events which occurs on or after the
Effective Date: (i) after a Change of Control (as defined in Section 7.1), any
material reduction of the Executive’s then existing annual base salary, except
to the extent the annual base salary of all other executive officers at levels
similar to Executive is similarly reduced (provided such reduction does not
exceed fifteen percent (15%) of Executive’s then existing annual base salary);
(ii) after a Change of Control, any material reduction in the package of
benefits and incentives, taken as a whole, provided to the Executive (except
that employee contributions may be raised to the extent of any cost increases
imposed by third parties) or any action by the Company which would materially
and adversely affect the Executive’s participation or reduce the Executive’s
benefits under any such plans, except to the extent that such benefits and
incentives of all other executive officers at levels similar to Executive are
similarly reduced; (iii) after a Change of Control, any material diminution of
the Executive’s duties and responsibilities, taken as a whole, excluding for
this purpose an isolated, insubstantial or inadvertent action not taken in bad
faith which is remedied by the Company immediately after notice thereof is given
by the Executive; (iv) after a Change of Control, a requirement that the
Executive materially relocate to a work site that would increase the Executive’s
one-way commute distance by more than thirty-five (35) miles from his then
principal residence, unless the Executive accepts such relocation opportunity;
(v) any material breach by the Company of its obligations under this Agreement;
or (vi) any failure by the Company to obtain the assumption of this Agreement by
any successor or assign of the Company; provided, however, that the Executive
may not resign his employment for Good Reason unless: (A) the Executive has
provided the Company with at least 30 days prior written notice of the
Executive’s intent to resign for Good Reason (which notice must be provided
within 60 days following the occurrence of the event(s) purported to constitute
Good Reason); and (B) the Company has not remedied the alleged violation(s)
within 30-days following its receipt of the written notice of intent to resign
for Good Reason.
          2. Release. Effective as of the Effective Date, Section 9 of the
Agreement is hereby amended in its entirety to read as follows:
     9. Release. In exchange for the severance compensation and benefits
provided under this Agreement to which Executive would not otherwise be
entitled, Executive shall enter into and execute a release substantially in the
form attached hereto as Exhibit B, as may be

 

--------------------------------------------------------------------------------

 

revised and updated as determined to be appropriate by the Company (the
“Release”). Unless the Release is executed by Executive following termination of
employment, delivered to the Company within fifty (50) days following the
Executive’s termination of employment, and not subsequently revoked, the Company
shall not be required to provide any severance benefits pursuant to this
Agreement, any vesting of acceleration of Executive’s Awards as provided in this
Agreement shall not apply, and Executive’s Awards in such event shall vest or,
in the case of stock options, be exercisable following the date of Executive’s
termination only to the extent provided under their original terms in accordance
with the applicable plan and Award agreements.
          3. Exhibit A, Section 4.1. Effective as of the Effective Date,
Section 4.1(a)(ii) of Exhibit A to the Agreement is hereby amended to
incorporate the following proviso at the end thereof:
provided, however, that the terms of any such consulting arrangement shall not
provide for the provision of bona fide services to the Company to any extent
that would prevent Executive from having a Separation from Service.
          4. Section 409A. Effective as of the Effective Date, the Agreement is
hereby amended to incorporate a new Section therein to read in its entirety as
follows:
Notwithstanding anything contained in this Agreement to the contrary, to the
maximum extent permitted by applicable law, severance amounts payable pursuant
to this Agreement shall be made in reliance upon Treas. Reg.
Section 1.409A-1(b)(9) (Separation Pay Plans) or Treas. Reg. Section
1.409A-1(b)(4) (Short-Term Deferrals). For this purpose each installment payment
to which you are entitled under the severance pay provisions of this Agreement
shall be considered a separate and distinct payment. In addition, (i) Subject to
Section 9 of this Agreement, all severance payments payable pursuant this
Agreement shall commence within sixty (60) days after the Executive’s Separation
from Service, (ii) no amount deemed deferred compensation subject to
Section 409A shall be payable pursuant to the severance pay provisions of this
Agreement unless your termination of employment constitutes a Separation from
Service, and (ii) if you are deemed at the time of your separation from service
to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the
Code, then to the extent delayed commencement of any portion of the termination
benefits to which you are entitled under this Agreement is required in order to
avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such
portion of your termination benefits shall not be provided to you prior to the
earlier of (A) the expiration of the six-month period measured from the date of
your Separation from Service with the Company or (B) the date of your death.
Upon the earlier of such dates, all payments deferred pursuant to this paragraph
shall be paid in a lump sum to you, and any remaining payments due under this
Agreement shall be paid as otherwise provided herein. For purposes of this
Agreement, Separation from Service shall mean a “separation from service” within
the meaning of Treasury Regulation Section 1.409A-1(h). The determination of
whether you are a “specified employee” for purposes of Section 409A(a)(2)(B)(i)
of the Code as of the time of your separation from service shall be made by the
Company in accordance with the terms of Section 409A of the Code and applicable
guidance thereunder (including without limitation Treas. Reg.
Section 1.409A-1(i) and any successor provision thereto). The payment of any
reimbursement of any expense under this Agreement (including without limitation,
any Gross-Up Payments

 

--------------------------------------------------------------------------------

 

pursuant to Section 7.3 of this Agreement) shall be made no later than
December 31 of the year following the year in which the expense was incurred.
The amount of expenses reimbursed in one year shall not affect the amount
eligible for reimbursement in any subsequent year. The payment of any bonus
earned pursuant to this Agreement shall be made no later than two and one-half
months following the end of the fiscal year in which such bonus was earned.
          2. No Other Changes. Except as provided in this Amendment, the
Agreement shall remain in full force and effect.
     IN WITNESS WHEREOF, the Company has caused this Amendment to be executed by
its duly authorized officer and the Executive has executed this Amendment as of
the Effective Date.

                  WATSON PHARMACEUTICALS, INC.       EXECUTIVE    
 
               
By:
  /s/ CLARE CARMICHAEL       /s/ THOMAS R. RUSSILLO    
 
               
Its:
  SVP Human Resources       Thomas R. Russillo    
 
                Date: December 29, 2008       Date: December 29, 2008